Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents

Medicinal Research Reviews

Volumn 32, Issue 4, 2012, Pages 868-905

  McConathy, Jonathan ^a   Yu, Weiping ^b   Jarkas, Nachwa ^b   Seo, Wonewoo ^b   Schuster, David M ^b   Goodman, Mark M ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Amino acid radiolabeling; PET; Radiohalogens; SPECT; Tumor imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1 AMINOCYCLOBUTANECARBOXYLIC ACID; 1 AMINOCYCLOPROPANECARBOXYLIC ACID; ALANINE; AMINO ACID TRANSPORTER; BROMINE 76; CARBON 11; CARBON 14; CARBOXYLIC ACID; CHROMIUM CHLORIDE; CYCLOLEUCINE; FLUORINE 18; GLUTAMINE; HETERODIMER; HISTIDINE; INDIUM 111; IODINE; IODINE 123; IODINE 124; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; METHIONINE; PHENYLALANINE; SERINE; SODIUM IODIDE I 131; TOSITUMOMAB I 131; TRACER; TRITIUM; TYROSINE; UNINDEXED DRUG;

ASCITES; BIOLOGICAL ACTIVITY; BONE TUMOR; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; BREAST TUMOR; CANCER CELL; CELL DIVISION; CELL GROWTH; CHROMATOGRAPHY; CLINICAL EVALUATION; COHORT ANALYSIS; COVALENT BOND; CYCLOTRON; EHRLICH ASCITES TUMOR; GLIOBLASTOMA; GLIOSARCOMA; HALF LIFE TIME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; ISOTOPE LABELING; LIVER CANCER; LUNG CANCER; LUNG TUMOR; METASTASIS; MULTIGENE FAMILY; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSMOLALITY; OSMOTIC STRESS; PH; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN SYNTHESIS; RECURRENT CANCER; REVIEW; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER;

AMINO ACIDS; FLUORINE RADIOISOTOPES; HUMANS; ISOTOPE LABELING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84863823322     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20250     Document Type: Review

References (168)

1. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, Hosokawa M, Kohanawa M, Tamaki N. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551-1555.
2. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317-322.
3. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274-292.
4. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:69-85.
5. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics 1999;19:61-77; quiz 150-151.
6. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007;48:1468-1481.
7. 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47:904-911.
8. McConathy J, Goodman MM. Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev 2008;27:555-573.
9. 18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-1470.
10. 11C]methionine uptake in brain tumours: Initial results of a comparative study. Eur J Nucl Med 2000;27:542-549.
11. 18F-DOPA PET: A prospective, diagnostic accuracy study. Lancet Oncol 2006;7:728-734.
12. 18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: Basic aspects and emerging clinical applications. J Nucl Med 2008;49:573-586.
13. Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, Sluiter WJ, de Vries EG, Links TP. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009;94:3922-3930.
14. 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008;26:1489-1495.
15. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007;48:56-63.
16. 18F-FACBC in humans. J Nucl Med 2007;48:1017-1020.
17. 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 2006;47:256-261.
18. 18F]Fluoroethyl)-L-tyrosine (FET): A tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 2002;29:1039-1046.
19. 18F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging 2002;29:648-654.
20. 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol 2009;36:681-686.
21. Beugnet A, Tee AR, Taylor PM, Proud CG. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J 2003;372:555-566.
22. Fuchs BC, Finger RE, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 2007;293:C55-C63.
23. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin Cancer Biol 2005;15:254-266.
24. Hyde R, Hajduch E, Powell DJ, Taylor PM, Hundal HS. Ceramide down-regulates System A amino acid transport and protein synthesis in rat skeletal muscle cells. FASEB J 2005;19:461-463.
25. Goberdhan DC, Ogmundsdottir MH, Kazi S, Reynolds B, Visvalingam SM, Wilson C, Boyd CA. Amino acid sensing and mTOR regulation: Inside or out? Biochem Soc Trans 2009;37:248-252.
26. Jager PL, Franssen EJ, Kool W, Szabo BG, Hoekstra HJ, Groen HJ, de Vries EG, van Imhoff GW, Vaalburg W, Piers DA. Feasibility of tumor imaging using L-3-[iodine-123]-iodo-alpha-methyl-tyrosine in extracranial tumors. J Nucl Med 1998;39:1736-1743.
27. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-445.
28. 18F-Fluoroethyl)-L-tyrosine in peripheral tumors: First clinical results. J Nucl Med 2005;46:411-416.
29. Sordillo PP, DiResta GR, Fissekis J, Conti P, Benua RS, Yeh SD, Laughlin JS. Tumor imaging with carbon-11 labeled alpha-aminoisobutyric acid (AIB) in patients with malignant melanoma. Am J Physiol Imaging 1991;6:172-175.
30. 11C]L-methionine uptake in gliomas. Neurosurgery 1989;25:720-728.
31. 11C-methionine in cerebral glioma patients studied with PET. Acta Neurochir (Wien) 1990;104:8-12.
32. Goodman MM, Kabalka GW, Meng X, Waterhouse RN, Longford CPD. In: Kabalka GW, Buncel E, editors. Synthesis and applications of isotopes and isotopically labelled compounds. Facile radiiodine incorporation via organometallics. Amsterdam: Elsevier; 1992. pp 353-358.
33. Goodman MM. In: Hubner KF, Buonocore E, Collmann J, Kabalka GW, editors. Clinical positron emission tomography. Automated synthesis of radiotracers for positron emission tomography applications. St. Louis, MO: Mosby-Year Book, Inc.; 1991. pp 110-122.
34. 124I. Appl Radiat Isot 2002;56:673-679.
35. Herzog H, Tellmann L, Scholten B, Coenen HH, Qaim SM. PET imaging problems with the non-standard positron emitters Yttrium-86 and Iodine-124. Q J Nucl Med Mol Imaging 2008;52:159-165.
36. Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: Indications and procedures. Best Pract Res Clin Endocrinol Metab 2008;22:989-1007.
37. Macklis RM. Radioimmunotherapy as a therapeutic option for non-Hodgkin's lymphoma. Semin Radiat Oncol 2007;17:176-183.
38. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2010;40:153-163.
39. Zhou D, Sharp TL, Fettig NM, Lee H, Lewis JS, Katzenellenbogen JA, Welch MJ. Evaluation of a bromine-76-labeled progestin 16alpha, 17alpha-dioxolane for breast tumor imaging and radiotherapy: In vivo biodistribution and metabolic stability studies. Nucl Med Biol 2008;35:655-663.
40. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteins introduction. Pflugers Arch 2004;447:465-468.
41. Closs EI, Boissel JP, Habermeier A, Rotmann A. Structure and function of cationic amino acid transporters (CATs). J Membr Biol 2006;213:67-77.
42. Verrey F. System L: Heteromeric exchangers of large, neutral amino acids involved in directional transport. Pflugers Arch 2003;445:529-533.
43. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: The SLC7 family of amino acid transporters. Pflugers Arch 2004;447:532-542.
44. Kanai Y, Hediger MA. The glutamate and neutral amino acid transporter family: Physiological and pharmacological implications. Eur J Pharmacol 2003;479:237-247.
45. Kanai Y, Hediger MA. The glutamate/neutral amino acid transporter family SLC1: Molecular, physiological and pharmacological aspects. Pflugers Arch 2004;447:469-479.
46. Li R, Younes M, Frolov A, Wheeler TM, Scardino P, Ohori M, Ayala G. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res 2003;23:3413-3418.
47. Witte D, Ali N, Carlson N, Younes M. Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res 2002;22:2555-2557.
48. Shennan DB, Thomson J. Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol Rep 2008;20:885-889.
49. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H. L-Type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006;119:484-492.
50. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H. Human L-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001;1514:291-302.
51. 18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol 1993;20:895-899.
52. Langen KJ, Broer S. Molecular transport mechanisms of radiolabeled amino acids for PET and SPECT. J Nucl Med 2004;45:1435-1436.
53. Paans AM, Pruim J, van Waarde A, Willemsen AT, Vaalburg W. Radiolabelled-tyrosine for the measurement of protein synthesis rate in vivo by positron emission tomography. Baillieres Clin Endocrinol Metab 1996;10:497-510.
54. Pruim J, Willemsen AT, Molenaar WM, van Waarde A, Paans AM, Heesters MA, Go KG, Visser GM, Franssen EJ, Vaalburg W. Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 1995;197:221-226.
55. 11C]leucine and PET with correction for recycling of tissue amino acids: II. Validation in rhesus monkeys. J Cereb Blood Flow Metab 2005;25:629-640.
56. 11C]-leucine PET: Incorporation of factors for large neutral amino acids in plasma and for amino acids recycled from tissue. J Nucl Med 2006;47:1787-1795.
57. Bussolati O, Uggeri J, Belletti S, Dallasta V, Gazzola GC. The stimulation of Na, K, Cl cotransport and of system A for neutral amino acid transport is a mechanism for cell volume increase during the cell cycle. FASEB J 1996;10:920-926.
58. Saier MH, Daniels GA, Boerner P, Lin J. Neutral amino-acid transport-systems in animal-cells: Potential targets of oncogene action and regulators of cellular growth. J Membr Biol 1988;104:1-20.
59. Kondoh N, Imazeki N, Arai M, Hada A, Hatsuse K, Matsuo H, Matsubara O, Ohkura S, Yamamoto M. Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues. Int J Oncol 2007;31:81-87.
60. Gupta N, Prasad PD, Ghamande S, Moore-Martin P, Herdman AV, Martindale RG, Podolsky R, Mager S, Ganapathy ME, Ganapathy V. Up-regulation of the amino acid transporter ATB(0, +) (SLC6A14) in carcinoma of the cervix. Gynecol Oncol 2006;100:8-13.
61. 0, + (SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta 2005;1741:215-223.
62. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006;13:1109-1120.
63. 18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: A comparative study with stereotactic biopsy. Eur J Nucl Med 1999;26:144-151.
64. Weber W, Bartenstein P, Gross MW, Kinzel D, Daschner H, Feldmann HJ, Reidel G, Ziegler SI, Lumenta C, Molls M, Schwaiger M. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997;38:802-808.
65. 124IMT and first clinical results. J Nucl Med 1990;31:281-286.
66. 18F]fluoroethyl)-L-tyrosine: Uptake mechanisms and clinical applications. Nucl Med Biol 2006;33:287-294.
67. 123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med 2004;45:374-381.
68. 18F-FDOPA kinetics in brain tumors. J Nucl Med 2007;48:1651-1661.
69. Conti PS, Sordillo PP, Schmall B, Benua RS, Bading JR, Bigler RE, Laughlin JS. Tumor imaging with carbon-11 labeled alpha-aminoisobutyric acid (AIB) in a patient with advanced malignant melanoma. Eur J Nucl Med 1986;12:353-356.
70. Schmall B, Conti PS, Bigler RE, Zanzonico PB, Reiman RE, Benua RS, Yeh SD, Dahl JR, Lee R, Laughlin JS. Imaging studies of patients with malignant fibrous histiocytoma using C-11-alpha-aminoisobutyric acid (AIB). Clin Nucl Med 1987;12:22-26.
71. 11C]alpha-methylaminoisobutyric acid in untreated head and neck cancer studied by PET. Eur J Nucl Med Mol Imaging 2003;30:72-77.
72. Mackenzie B, Erickson JD. Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family. Pflugers Arch 2004;447:784-795.
73. Franchi-Gazzola R, Dall'Asta V, Sala R, Visigalli R, Bevilacqua E, Gaccioli F, Gazzola GC, Bussolati O. The role of the neutral amino acid transporter SNAT2 in cell volume regulation. Acta Physiol (Oxf) 2006;187:273-283.
74. Franchi-Gazzola R, Gaccioli F, Bevilacqua E, Visigalli R, Dall'Asta V, Sala R, Varoqui H, Erickson JD, Gazzola GC, Bussolati O. The synthesis of SNAT2 transporters is required for the hypertonic stimulation of system A transport activity. Biochim Biophys Acta 2004;1667:157-166.
75. Hyde R, Taylor PM, Hundal HS. Amino acid transporters: Roles in amino acid sensing and signalling in animal cells. Biochem J 2003;373:1-18.
76. Christensen HN, Oxender DL, Liang M, Vatz KA. The use of N-methylation to direct route of mediated transport of amino acids. J Biol Chem 1965;240:3609-3616.
77. Shotwell MA, Kilberg MS, Oxender DL. The regulation of neutral amino acid transport in mammalian cells. Biochim Biophys Acta 1983;737:267-284.
78. Arriza JL, Kavanaugh MP, Fairman WA, Wu YN, Murdoch GH, North RA, Amara SG. Cloning and expression of a human neutral amino acid transporter with structural similarity to the glutamate transporter gene family. J Biol Chem 1993;268:15329-15332.
79. +-dependent neutral amino acid transporter. J Biol Chem 1996;271:14883-14890.
80. Babu E, Kanai Y, Chairoungdua A, Kim DK, Iribe Y, Tangtrongsup S, Jutabha P, Li Y, Ahmed N, Sakamoto S, Anzai N, Nagamori S, Endou H. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem 2003;278:43838-43845.
81. Bodoy S, Martin L, Zorzano A, Palacin M, Estevez R, Bertran J. Identification of LAT4, a novel amino acid transporter with system L activity. J Biol Chem 2005;280:12002-12011.
82. Palacin M, Estevez R, Bertran J, Zorzano A. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev 1998;78:969-1054.
83. Yoshimoto T, Yoshimoto E, Meruelo D. Molecular cloning and characterization of a novel human gene homologous to the murine ecotropic retroviral receptor. Virology 1991;185:10-17.
84. Hammermann R, Brunn G, Racke K. Analysis of the genomic organization of the human cationic amino acid transporters CAT-1, CAT-2 and CAT-4. Amino Acids 2001;21:211-219.
85. MacLeod CL, Finley K, Kakuda D, Kozak CA, Wilkinson MF. Activated T cells express a novel gene on chromosome 8 that is closely related to the murine ecotropic retroviral receptor. Mol Cell Biol 1990;10:3663-3674.
86. Closs EI, Albritton LM, Kim JW, Cunningham JM. Identification of a low affinity, high capacity transporter of cationic amino acids in mouse liver. J Biol Chem 1993;268:7538-7544.
87. Closs EI, Graf P, Habermeier A, Cunningham JM, Forstermann U. Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: Three related carriers with distinct transport properties. Biochemistry 1997;36:6462-6468.
88. Hosokawa H, Sawamura T, Kobayashi S, Ninomiya H, Miwa S, Masaki T. Cloning and characterization of a brain-specific cationic amino acid transporter. J Biol Chem 1997;272:8717-8722.
89. Ito K, Groudine M. A new member of the cationic amino acid transporter family is preferentially expressed in adult mouse brain. J Biol Chem 1997;272:26780-26786.
90. Vekony N, Wolf S, Boissel JP, Gnauert K, Closs EI. Human cationic amino acid transporter hCAT-3 is preferentially expressed in peripheral tissues. Biochemistry 2001;40:12387-12394.
91. Sperandeo MP, Borsani G, Incerti B, Zollo M, Rossi E, Zuffardi O, Castaldo P, Taglialatela M, Andria G, Sebastio G. The gene encoding a cationic amino acid transporter (SLC7A4) maps to the region deleted in the velocardiofacial syndrome. Genomics 1998;49:230-236.
92. +L. A candidate gene for lysinuric protein intolerance. J Biol Chem 1998;273:32437-32445.
93. +L-type by heterodimers of 4F2hc/CD98 and members of the glycoprotein-associated amino acid transporter family. EMBO J 1999;18:49-57.
94. Sloan JL, Mager S. Cloning and functional expression of a human Na(+) and Cl(-)-dependent neutral and cationic amino acid transporter B(0+). J Biol Chem 1999;274:23740-23745.
95. Bertran J, Werner A, Chillaron J, Nunes V, Biber J, Testar X, Zorzano A, Estivill X, Murer H, Palacin M. Expression cloning of a human renal cDNA that induces high affinity transport of L-cystine shared with dibasic amino acids in Xenopus oocytes. J Biol Chem 1993;268:14842-14849.
96. Carter SK. Chemotherapy fact sheet: 1-Amino-cyclopentanecarboxylic acid (NSC-1026). Publications Section, Program Analysis Branch, Chemotherapy, National Cancer InstitutePublications Section, Program Analysis Branch, Chemotherapy, National Cancer Institute, 1970.
97. 11C-1-aminocyclopentanecarboxylic acid, a potential agent for cancer detection. J Nucl Med 1976;17:748-751.
98. 11C] carboxylic acid: Preliminary clinical trials with single-photon detection. J Nucl Med 1977;18:1215-1221.
99. 11C]carboxylic acid, a potential tumor-seeking agent. J Nucl Med 1979;20:1055-1061.
100. Goodman M, DeVinney J, Kabalka G, Ladetsky M, Hubner K, Meyer M, Lambert S. Microprocessor-controlled open vessel system for the production of no-carrier-added-1-aminocyclobutane-1-carboxylic acid. J Label Compd Radiopharm 1991;30:184-186.
101. Hubner KF, Krauss S, Washburn LC, Gibbs WD, Holloway EC. Tumor detection with 1-aminocyclopentane and 1-aminocyclobutane C-11-carboxylic acid using positron emission computerized tomography. Clin Nucl Med 1981;6:249-252.
102. 11C]-ACBC) for detecting recurrent brain tumors. Clin Positron Imaging 1998;1:165-173.
103. Berlinguet L, Begin N, Babineau LM. Autoradiographic studies of the distribution of 1-aminocyclopentane carboxylic acid in normal and cancerous mice. Can J Biochem Physiol 1962;40:1111-1114.
104. Sterling WR, Henderson JF, Mandel HG, Smith PK. The metabolism of 1-aminocyclopentane-1-carboxylic acid in normal and neoplastic tissues. Biochem Pharmacol 1962;11:135-145.
105. Washburn LC, Sun TT, Anon JB, Hayes RL. Effect of structure on tumor specificity of alicyclic alpha-amino acids. Cancer Res 1978;38:2271-2273.
106. 18F]FACBC: Improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot 2003;58:657-666.
107. Shoup TM, Goodman MM. Synthesis of [F-18]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC): A PET tracer for tumor delineation. J Label Compd Radiopharm 1999;42:215-225.
108. 18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 1999;40:331-338.
109. 18F]fluorocyclobutyl-1-carboxylic acid as a potential positron emission tomography brain tumor imaging agent. Bioorg Med Chem 2009;17:1982-1990.
110. Yu W, Williams L, Camp VM, Olson JJ, Goodman MM. Synthesis and biological evaluation of anti-1-amino-2-[(18)F]fluoro-cyclobutyl-1-carboxylic acid (anti-2-[(18)F]FACBC) in rat 9L gliosarcoma. Bioorg Med Chem Lett 2010;20:2140-2143.
111. 18F-FACPC and its biological evaluation in 9L gliosarcoma cells and 9L tumor bearing rats. J Label Compd Radiopharm 2009;52:S194.
112. 18F]fluoromethyl-cyclobutane-1-carboxylic acid (FMACBC), potential PET ligands for tumor detection. J Med Chem 2002;45:2250-2259.
113. 18F]fluoro-2-methylbutanoic acid (FAMB): Relationship of amino acid transport to tumor imaging properties of branched fluorinated amino acids. Nucl Med Biol 2003;30:477-490.
114. Moon BS, Lee TS, Lee KC, An GI, Cheon GJ, Lim SM, Choi CW, Chi DY, Chun KS. Syntheses of F-18 labeled fluoroalkyltyrosine derivatives and their biological evaluation in rat bearing 9L tumor. Bioorg Med Chem Lett 2007;17:200-204.
115. 123I]iodo-3-(E)-butenoic acid for brain tumor imaging with single photon emission computerized tomography. J Med Chem 2007;50:6718-6721.
116. Yu WP, McConathy J, Williams L, Camp VM, Malveaux EJ, Zhang ZB, Olson JJ, Goodman MM. Synthesis, radiolabeling, and biological evaluation of (R)- and (S)-2-amino-3-[F-18]fluoro-2-methylpropanoic acid (FAMP) and (R)- and (S)-3-[F-18]fluoro-2-methyl-2-N-(methylamino)propanoic acid (NMeFAMP) as potential PET radioligands for imaging brain tumors. J Med Chem 2010;53:876-886.
117. 18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 2007;48:46-55.
118. 18F]FACBC) with PET in renal carcinoma. Mol Imaging Biol 2009;11:434-438.
119. Yu W, Williams L, Malveaux E, Camp VM, Olson JJ, Goodman MM. Synthesis and evaluation of [I-123] labeled iodovinyl amino acids syn-, anti-1-amino-3-[2-iodoethenyl]-cyclobutane-1-carboxylic acid, and 1-amino-3-iodomethylene-cyclobutane-1-carboxylic acid as potential SPECT brain tumor imaging agents. Bioorg Med Chem Lett 2008;18:1264-1268.
120. 123I]iodo-3-(E)-butenoic acid for brain tumor imaging with single photon emission computerized tomography. J Med Chem 2007;50:6718-6721.
121. 11C in normal and prostate cancer-bearing rat after chemotherapy. Eur J Nucl Med 1981;6:535-538.
122. Fissekis JD, Nielsen C, Dahl JR. An efficient, remote-control synthesis of C-11 labeled branched amino-acids. J Label Compd Radiopharm 1986;23:1083-1084.
123. Prenant C, Theobald A, Siegel T, Joachim J, Weber K, Haberkorn U, Oberdorfer F. C-11 labeled analogs of alanine by the Strecker synthesis. J Label Compd Radiopharma 1995;36:579-586.
124. Oberdorfer F, Zobeley A, Weber K, Prenant C, Haberkorn U, Maierborst W. Preparation of alpha-[3-C-11]aminoisobutyric acid from an azadisilolidine derivative of alanine. J Label Compd Radiopharm 1993;33:345-353.
125. 11C]methyl triflate and HPLC metabolite analysis of plasma samples after intravenous administration in man. J Label Compd Radiopharm 2000;43:1013-1021.
126. Betz AL, Goldstein GW. Polarity of the blood-brain barrier: Neutral amino acid transport into isolated brain capillaries. Science 1978;202:225-227.
127. Blasberg RG, Fenstermacher JD, Patlak CS. Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J Cereb Blood Flow Metab 1983;3:8-32.
128. Uehara H, Miyagawa T, Tjuvajev J, Joshi R, Beattie B, Oku T, Finn R, Blasberg R. Imaging experimental brain tumors with 1-aminocyclopentane carboxylic acid and alpha-aminoisobutyric acid: Comparison to fluorodeoxyglucose and diethylenetriaminepentaacetic acid in morphologically defined tumor regions. J Cereb Blood Flow Metab 1997;17:1239-1253.
129. Schaider H, Haberkorn U, Berger MR, Oberdorfer F, Morr I, vanKaick G. Application of alpha-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line. Eur J Nucl Med 1996;23:55-60.
130. 11C]-alpha-aminoisobutyric acid for tumor detection and amino acid transport measurement: Spontaneous canine tumor studies. Eur J Nucl Med 1985;10:48-55.
131. Conti PS, Sordillo EM, Sordillo PP, Schmall B. Tumor localization of alpha-aminoisobutyric acid (AIB) in human melanoma heterotransplants. Eur J Nucl Med 1985;10:45-47.
132. 11C] methylaminoisobutyric acid, a tracer for PET studies on system A amino acid transport in vivo. Eur J Nucl Med 2001;28:847-854.
133. Asola MR, Virtanen KA, Peltoniemi P, Nagren K, Yu M, Mattila K, Jyrkkio S, Metsarinne K, Nuutila P, Knuuti J. Amino acid uptake in the skeletal muscle measured using [11C]methylaminoisobutyrate (MEAIB) and PET. Eur J Nucl Med Mol Imaging 2002;29:1485-1491.
134. Asola M, Virtanen K, Nagren K, Helin S, Taittonen M, Kastarinen H, Anderstam B, Knuuti J, Metsarinne K, Nuutila P. Amino-acid-based peritoneal dialysis solution improves amino-acid transport into skeletal muscle. Kidney Int 2008;73:S131-S136.
135. Christensen HN, Oxender DL. The acid strength of the amino group as a factor in the transport of amino acids. Biochim Biophys Acta 1963;74:386-391.
136. Shiba K, Mori H, Hisada K. Analogs of alpha-aminoisobutyric-acid with various alkyl-groups as potential tumor imaging agents: Effects of chain-length on tumor and normal tissue-specificity. Nucl Med Commun 1989;10:751-758.
137. Bergmann ED, Shani A. 12. Organic fluorine compounds. XXVII. Fluorinated α-aminoisobutyric acids. J Chem Soc 1963:3462-3463.
138. 18F]fluoro-2-methyl-2-(methylamino)propanoic acid. J Med Chem 2002;45:2240-2249.
139. Boulton LT, Stock HT, Raphy J, Horwell DC. Generation of unnatural alpha, alpha-disubstituted amino acid derivatives from cyclic sulfamidates. J Chem Soc Perkin Trans 1 1999:1421-1429.
140. Posakony JJ, Tewson TJ. Substitution reactions of hindered cyclic sulfamidates. Synthesis-Stuttgart 2002:859-864.
141. Melenedz RE, Lubell WD. Synthesis and reactivity of cyclic sulfamidites and sulfamidates. Tetrahedron 2003;59:2581-2616.
142. Hanson RW, Law HD. 238. Substituted diphenylmethyl protecting groups in peptide synthesis. J Chem Soc 1965:7285-7297.
143. Ludwig J, Lehr M. Convenient synthesis of pyrrole- and indolecarboxylic acid tert-butylesters. Synthetic Commun 2004;34:3691-3695.
144. Widmer U. A convenient preparation of tert-butyl esters. Synthesis-Stuttgart 1983:135-136.
145. Posakony JJ, Grierson JR, Tewson TJ. New routes to N-alkylated cyclic sulfamidates. J Org Chem 2002;67:5164-5169.
146. 18FDG preparations and detection of the chemical impurity 2-deoxy-2-chloro-D-glucose. Int J Rad Appl Instrum A 1992;43:1313-1322.
147. 131I]iodo-9-telluraheptadecanoic acid, a potential imaging agent. J Med Chem 1982;25:613-618.
148. 123I]Iodo-alpha-methyl-L-tyrosine: Uptake mechanisms and clinical applications. Nucl Med Biol 2002;29:625-631.
149. 123I]iodo-alpha-methyl-L-tyrosine transport and 4F2 antigen expression in human glioma cells. Nucl Med Biol 2001;28:5-11.
150. Takai K, Nitta K, Utimoto K. Simple and selective method for Rcho-](E)-Rch = Chx conversion by means of a Chx3-Crcl2 system. J Am Chem Soc 1986;108:7408-7410.
151. Benrabh H, Lefauconnier JM. Blood-endothelial cell and blood-brain transport of L-proline, alpha-aminoisobutyric acid, and L-alanine. Neurochem Res 1996;21:1227-1235.
152. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: Histopathological evaluation of a series. Surg Neurol 1998;49:436-440.
153. 18F] FAMP as PET tumor imaging candidates. J Label Compd Radiopharm 2005;48:S34.
154. 18F]FAMP as PET tumor imaging agent. J Nucl Med 2004;45:168P-169P.
155. Demko ZP, Sharpless KB. An intramolecular [2 + 3] cycloaddition route to fused 5-heterosubstituted tetrazoles. Org Lett 2001;3:4091-4094.
156. 18F]fluoroethylazide for positron emission tomography. Bioconjug Chem 2007;18:989-993.
157. Mindt TL, Struthers H, Brans L, Anguelov T, Schweinsberg C, Maes V, Tourwe D, Schibli R. "Click to chelate": Synthesis and installation of metal chelates into biomolecules in a single step. J Am Chem Soc 2006;128:15096-15097.
158. 18F]fluoroethyl)-1H-[1, 2, 3]triazol-4-yl]propanoic acid for brain tumor imaging. Mol Imaging 2010;9:329-342.
159. Gazzola GC, Dall'Asta V, Franchi-Gazzola R, White MF. The cluster-tray method for rapid measurement of solute fluxes in adherent cultured cells. Anal Biochem 1981;115:368-374.
160. Eros D, Orfi L, Csuka I, Keri G, Hrabak A. Binding specificity of the L-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1. Amino Acids 2009;36:483-492.
161. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-534.
162. Massi D, De Nisi MC, Franchi A, Mourmouras V, Baroni G, Panelos J, Santucci M, Miracco C. Inducible nitric oxide synthase expression in melanoma: Implications in lymphangiogenesis. Mod Pathol 2009;22:21-30.
163. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, Hoskin PJ. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: A phase I study. Lancet Oncol 2007;8:111-118.
164. Basuroy UK, Gerner EW. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J Biochem 2006;139:27-33.
165. Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I. Role of polyamines derived from arginine in differentiation and proliferation of human blood cells. Biol Pharm Bull 2006;29:234-239.
166. Oredsson SM. Polyamine dependence of normal cell-cycle progression. Biochem Soc Trans 2003;31:366-370.
167. Lind DS. Arginine and cancer. J Nutr 2004;134:2837S-2841S; discussion 2853S.
168. Wheatley DN. Arginine deprivation and metabolomics: Important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin Cancer Biol 2005;15:247-253.